Simpler HIV pill shows promise for teens in small trial
NCT ID NCT03682848
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a once-daily pill containing two HIV drugs (dolutegravir and lamivudine) in 32 adolescents aged 12 to 17 who had never taken HIV medication before. The goal was to see if this simpler two-drug regimen could control the virus as well as standard three-drug combinations, while potentially causing fewer long-term side effects. After 48 weeks, the main measure was the percentage of teens with undetectable virus levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dolutegravir/Lamivudine (DTG/3TC) fixed-dose combination pill
What this could lead to
If successful, this could offer a simpler, less toxic daily HIV treatment option for adolescents, reducing long-term side effects while keeping the virus under control.
What could go wrong
This is a small, single-arm study with only 32 participants, so results may not apply to all teens. HIV treatment must be taken lifelong, and the virus could still become resistant or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Kericho, 20200, Kenya
-
GSK Investigational Site
Kisumu, 40100, Kenya
-
GSK Investigational Site
Cape Town, 7500, South Africa
-
GSK Investigational Site
Durban, 4001, South Africa
-
GSK Investigational Site
Johannesburg, 1862, South Africa
-
GSK Investigational Site
Bangkok, 10330, Thailand
-
GSK Investigational Site
Bangkok, 10700, Thailand
-
GSK Investigational Site
Chiang Mai, 50200, Thailand